Clearstream Share Discussion Threads

[hastings] 14/10/2010 22:22

Very lonely here!!

[hastings] 11/10/2010 13:02

Results in line with forecasts today and now set for a decent 2011 and beyond.
Clearly not on the radar of many...yet, but should be.
PER of just over 6 for next year compared to sector average of 12 and which should be easily achievable given the strong 2nd half perforamnce.
Current record order book and confidence high going into next year.
Further milestone payemnts should also boost next years figures.

[hastings] 26/9/2010 21:08

What a decent little number CTN looks to be, yet not much interest out there.
Some impressive growth, with sales rising from around£2M to £12M from 2005 to last year and profitable too.
Focused on the health market producing catheters and stents it already has alliances with some big names like Johnson & Johnson. House Broker has £4.7M Pre-Tax in for next year giving a Fwd PER of 6 !
Jam packed with Institutions,too


Major Shareholders Amount % Holding
Legal & General Group PLC 6,100,000 13.24
Michael David Love • 4,386,266 9.52
Gartmore Investment Ltd 3,147,676 6.83
ICC Venture Capital Fund 3,093,240 6.71
Blackrock Inc 3,000,000 6.51
Andrew John Jones • 2,083,777 4.52
Enterprise Ireland 1,927,952 4.18
Noble Fund Managers Nominee 1,875,000 4.07
Royal Bank of Scotland Group PLC 1,460,207 3.17
Henderson Global Investors Ltd 1,401,019 3.04

[puku] 26/9/2010 18:39

a good find hastings - I like these "quiet" shares. Their trading update in Feb was very positive medium term with approvals in US and China . Poor interim but new areas should feed into Finals. I bought at 24p and expect 50p in 18 months.

[kktj] 17/9/2010 10:59

Sorry wrong board!

[richardwong78] 15/9/2010 17:54

I think the share has bottomed out at the 22 p level. Hopefully some good news will push it back to 30 p and beyond.

[themoneymonster2] 15/9/2010 08:24

Mentioned in Tom Bulford's Penny sleuth last night.

[investinggarden] 13/1/2010 18:47

US approval for ClearStream

[cestnous] 03/11/2009 14:12

Good news from ClearStream
Created:3 November 2009Written by:Nigel Bolitho
Although ClearStream's 2008-09 results include a one-off gain of €1.4m following the signing of a new contract for peripheral catheters with CR Bard, it's more of a hello payment as there is likely to be a second tranche of money totalling $500,000 (£306,442) this year and a bit more in 2010-2011. So on a like-for-like basis ClearStream reported a 2008-09 profit of €500,000 (£449,256).

Advertising

That's still an impressive turnaround. Equally impressive is the list of regulatory approvals including five conformity marks in the EU and FDA approval for the ReeKross family of catheters used in the treatment of extreme cases of critical limb ischemia. This furring up of leg arteries is often called diabetic food and will turn gangrenous unless treated: in its presentation ClearStream reports that in Europe a lower limb is amputated every four minutes. On the back of regulatory approvals, the company was able to register 62 devices in new countries.

And by concentrating on peripheral catheters and avoiding coronary catheters, the company is exploiting a higher-margin niche market. It has also acquired full rights to a drug-eluting stent.

Last year's sales breakdown also indicates how important catheter co-labelling sales with Bard and its rival Cordis will be in the all-important US market. In the 12 months American sales (including the Bard payment) jumped from €1.66m to €6.76m and co-labelling sales are expected to be significantly higher this year. In total 2009-10 turnover could be around €15.5m. But because of a doubling to €2m in sales and marketing costs, profits excluding one-off payments may be little changed at €500,000.



CLEARSTREAM TECHNOLOGIES (CTN)

ORD PRICE: 25p MARKET VALUE: £11.5m
TOUCH: 24-26p 12-MONTH HIGH: 40p LOW: 10p
DIVIDEND YIELD: nil PE RATIO: 4
NET ASSET VALUE: 15¢* NET CASH: €689,000



Year to 31 July Turnover (Em) Pre-tax profit (Em) Earnings per share (¢) Dividend per share (¢)
2005 2.65 -4.51 -34.00 nil
2006 5.26 -4.65 -23.00 nil
2007 9.18 -2.68 -11.19 nil
2008 9.21 -1.19 -4.54 nil
2009 13.87 1.93 6.70 nil
% change +51 - - -
Aim: Health care equipment.

£1 = €1.1172

* Including €1.99m intangibles, or 4¢ a share




Guide to the terms used in IC results tables.

More analysis of company results

More share tips and updates...

Check out our tip performance...


--------------------------------------------------------------------------------

IC VIEW
BuyClearStream's regulatory progress is impressive. We upgrade the shares from good value to buy.

Last IC view: Good value, 40p, 21 April 2009.

[investinggarden] 10/7/2009 15:26

Add recommendation from Growth Company Investor

[sichuk] 22/4/2009 10:38

Anyone here?

This is a copy of my iii posting; If anyone is interested..? RE: Results on 20/4/2009.

The results speak for themselves.

As expected;
NET profit in the last 6 months trading was delivered.
This being in the WEAKER trading half.
Revenue growth of 69%
Euro1/2M 5 year banking facility arranged.
Cash raised/Directors hold well over 10% of the company(Healthy ownership level)
26% increase in gross margins.
Now profitable (.37c/share)
11 new CE marks attained during the period. New products constantly being developed and introduced to market in areas where they know they can market-lead.

All this with only a market cap of £10M, yet this company is international and now growing at break-neck speed, especially in American clinical markets-but also growing in Jap and euro markets.

[kiwi10] 12/11/2008 07:21

ClearStream Technologies Group PLC
12 November 2008




ClearStream Technologies Group Plc


ClearStream Technologies Group Plc ('ClearStream'), the Irish medical device maker, is pleased to announce that the following directors have bought ordinary Euro0.125 shares in the Company as follows:


Director


Shares purchased


Price per share








Mike Love


460,000


20p

Andrew Jones


40,000


20p


Accordingly, the new beneficial interest of Mike Love and Andrew Jones are as follows:


Director


Beneficial interest in


Percentage of issued




Ordinary Euro0.125 shares


and voting share capital








Mike Love


3,136,266


10.83

Andrew Jones


2,019,674


6.97



Enquiries:


Andrew Jones, CEO, ClearStream Technologies Group plc


Tel: + 353 (0) 872 473 694

Paul Vann, Winningtons Financial


Tel: + 44 (0) 117 920 0092

Mike Coe, Blue Oar Securities Plc


Tel: + 44 (0) 117 933 0020


ABOUT CLEARSTREAM


ClearStream Technologies Group, based in Enniscorthy, Co. Wexford, Ireland is an innovative maker of medical devices used in interventional cardiology and interventional radiology, including catheters and stents. Its products are sold under its own brand and also to Original Equipment Manufacturers. The company is listed on the AIM market of the London Stock Exchange.



This information is provided by RNS
The company news service from the London Stock Exchange

[kiwi10] 12/11/2008 07:20

ClearStream Technologies Group PLC
11 November 2008




ClearStream Technologies Group Plc



ClearStream Technologies Group Plc ('ClearStream'), the Irish medical device maker, is pleased to announce that the following directors have bought ordinary Euro0.125 shares in the Company as follows:


Director


Shares purchased


Price per share








Mike Love


223,000


15p

Andrew Jones


108,666


15p

Pauline Oakes


61,344


15p


Accordingly, the new beneficial interest of Mike Love and Andrew Jones are as follows:


Director


Beneficial interest in


Percentage of issued




Ordinary Euro0.125 shares


and voting share capital








Mike Love


2,676,266


9.23

Andrew Jones


1,979,674


6.83

Pauline Oakes


234,022


0.81



Enquiries:


Andrew Jones, CEO, ClearStream Technologies Group plc


Tel: + 353 (0) 872 473 694

Paul Vann, Winningtons Financial


Tel: + 44 (0) 117 920 0092

Mike Coe, Blue Oar Securities Plc


Tel: + 44 (0) 117 933 0020


ABOUT CLEARSTREAM


ClearStream Technologies Group, based in Enniscorthy, Co. Wexford, Ireland is an innovative maker of medical devices used in interventional cardiology and interventional radiology, including catheters and stents. Its products are sold under its own brand and also to Original Equipment Manufacturers. The company is listed on the AIM market of the London Stock Exchange.



This information is provided by RNS
The company news service from the London Stock Exchange

[kiwi10] 11/11/2008 14:04

these look as though they are making the right sort of progress....not at the top of the leaderboard today but not far away....don't look as though they discussed very often though so can't be on many radars

[james t kirk] 13/3/2008 16:55

I didnt realise I was buying into such an unknown company - great trading statement and very little movement, but I'm happy to hold..

[james t kirk] 13/3/2008 08:26

Decided to take a small holding here, looks like its really sunk low and the company's turning around.

[currypasty] 31/10/2007 07:49

RNS Number:6525G
ClearStream Technologies Group PLC
31 October 2007


ClearStream Technologies Group plc

Continued Strong Sales Growth and Substantial Improvement in Gross Margins


ClearStream Technologies Group plc ('ClearStream') announces its preliminary
audited results for the year ended 31 July 2007. Quoted on AIM (stock code:
CTN), ClearStream is based in Enniscorthy, Ireland and is a specialist supplier
of medical devices used in the rapidly growing interventional medical market.


KEY POINTS:

Strong overall sales growth lead by growth in ClearStream brand sales
Progressive and significant reduction in losses across period
Substantial and progressive improvement across the reporting period in gross margins
ReeKross established as market leader in niche sector of peripheral market
Continued growth in Nimbus(R) Pico and Clearflex share of cardiology market
Successful manufacturing execution on major co-labelling distribution agreement
New distribution agreement signed opening opportunity in US market
International distributor network further strengthened and expanded
Continued progress in yield improvement, reduction in material costs and general
efficiencies

Trading results in close line with expectations:

2007 2006

Revenues Euro9.2M Euro5.3M
Loss before tax and goodwill amortisation (after R&D expenditure of Euro2.8M Euro4.6M
Euro1.4m (2006:Euro1.5m))
Loss before tax Euro3.2M Euro4.7M
Loss per share Euro0.13 Euro0.23
Cash and cash equivalents Euro0.22M Euro1.75M


On outlook, Chairman, Mike Love said:

"The Board's attention will be focused on expanding the ClearStream business,
moving to operational profitability and driving for further profitable growth.
We have ambitious plans with a coherent strategy for their realisation and
anticipate making further good progress across the year".

[hywel] 24/7/2007 20:33

Hi CurryPasty and now egoi, only just became aware of this company and have just ready every post and RNS released by the company. They seem to be doing well increasing sales but i'm just wondering with the constant need for R&D and new products whether this will be another one of those bio-techs that are serial loss makers. It's not been an auspicious start for the company. Any forecasts available for the company? Things do seem on the up though.

[egoi] 24/7/2007 16:29

Now two pieces of good news, despite the chart just opened my first position in this stock, just a nibble tho' for now.

[currypasty] 24/7/2007 07:13

RNS Number:7212A
ClearStream Technologies Group PLC
24 July 2007

ClearStream Technologies Group Plc announces that it has been informed that Mike
Love (Chairman) and Andrew Jones (Chief Executive) have exercised warrants at 55
pence per share over 57,552 and 10,395 ordinary shares of Euro0.125 each.

[currypasty] 18/7/2007 07:48

RNS Number:3831A
ClearStream Technologies Group PLC
18 July 2007

Trading Update





ClearStream Technologies Group Plc is pleased to announce that it expects sales
in the final quarter of its year ending 31 July 2007 to be the highest since its
flotation in November 2007. With the Company's products achieving increasing
traction in the market place, average monthly sales are now progressing towards
#1m per month and the Directors anticipate as a minimum that this level of
average monthly sales will be sustained into the new financial year. The
Directors are also confident that further healthy growth in sales can be
achieved going into 2008.



The Company expects its results for the year ending 31 July 2007 will be broadly
in line with expectations.



In addition the Company wishes to announce the retirement of Mr Frank Traynor as
a non executive director with immediate effect. The Board wishes to record its
thanks for his valuable contribution over his years of service.